Table 3.
Clinical outcomes.
| Overall | SARS-CoV-2 | RSV | Adenovirus | Rhinovirus | Influenza A and B | Metapneumovirus | Coronavirus | |
|---|---|---|---|---|---|---|---|---|
| n = 767 | n = 408 | n = 204 | n = 56 | n = 32 | n = 44 | n = 17 | n = 6 | |
| Outcome | ||||||||
| Need for O2 therapy | 110 (14.80) | 10 (2.49) | 69 (36.32) | 9 (16.07) | 10 (32.26) | 4 (9.30) | 5 (33.33) | 3 (50) |
| O2 high flow | 64 (8.34) | 4 (0.98) | 55 (26.96) | 1 (1.79) | 2 (6.25) | 1 (2.27) | 0 (0) | 1 (16.67) |
| Admission | 441 (57.50) | 115 (28.19) | 202 (99.02) | 45 (80.36) | 28 (87.50) | 30 (68.18) | 15 (88.24) | 6 (100) |
| Days of hospitalization > 3 | 286 (65.45) | 66 (58.93) | 151 (75.12) | 23 (51.11) | 15 (53.57) | 20 (66.67) | 10 (66.67) | 1 (16.67) |
| Antibiotic therapy | 132 (17.58) | 52 (12.78) | 26 (13.54) | 21 (37.50) | 12 (37.50) | 12 (29.27) | 6 (35.29) | 3 (50) |
| Complication | 72 (9.39) | 21 (5.15) | 33 (16.18) | 6 (10.71) | 4 (12.50) | 5 (11.36) | 3 (17.65) | 0 (0) |
| Mechanical ventilation | 13 (1.71) | 3 (0.74) | 7 (3.43) | 2 (3.57) | 1 (3.23) | 0 (0) | 0 (0) | 0 (0) |